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Carbon dioxide digital subtraction
angiography–assisted endovascular aortic
aneurysm repair in the azotemic patient
Alex Chao, MD, Kevin Major, MD, Subramanyan Ram Kumar, MD, Kevin Patel, MD, Israel Trujillo, BS,
Douglas B. Hood, MD, Vincent L. Rowe, MD, and Fred A. Weaver, MD, Los Angeles, Calif
Objective: This report analyzes the safety and efficacy of carbon dioxide digital subtraction angiography (CO2-DSA) for
EVAR in a group of patients with renal insufficiency compared with a concurrent group of patients with normal renal
function undergoing EVAR with iodinated contrast angiography (ICA).
Methods: Between 2003 and 2005, 100 consecutive patients who underwent EVAR using ICA, CO2-DSA, or both were
retrospectively reviewed, and preoperative, intraoperative, postoperative, and follow-up variables were collected. Patients
were divided into two groups depending on renal function and contrast used. Group I comprised patients with normal
renal function in whom ICA was used exclusively, and group II patients had a serum creatinine >1.5 mg/dL, and
CO2-DSA was used preferentially and supplemented with ICA, when necessary. The two groups were compared for the
outcomes of successful graft placement, renal function, endoleak type, and frequency, and the need for graft revision.
Comparisons were made using 2 analysis, Student t test, and the Fisher exact test.
Results: A total of 84 EVARs were performed in group I and 16 in group II. Patient demographics and risk factors were
similar between groups with the exception of serum creatinine, which was significantly increased in group II (1.8 mg/dL
vs 1.0 mg/dL P < .0005). All 100 endografts were successfully implanted. Patients in group II had longer fluoroscopy
times, longer operative times, and increased radiation exposure, and 13 of 16 patients required supplemental ICA. Mean
iodinated contrast use was 27 mL for group II vs 148 mL in group I (P < .0005). Mean postoperative serum creatinine
was unchanged from baseline, and 30-day morbidity was similar for both groups. No patient required dialysis. No
patients died. Perioperatively, and at 1 and 6months, the endoleak type and incidence and need for endograft revision was
no different between groups.
Conclusions: CO2-DSA is safe, can be used to guide EVAR, and provides outcomes similar to ICA-guided EVAR.
CO2-DSA protects renal function in the azotemic patient by lessening the need for iodinated contrast and associated
nephrotoxicity, but with the tradeoff of longer fluoroscopy and operating room times and increased radiation exposure.
(J Vasc Surg 2007;45:451-60.)Endovascular aortic aneurysm repair (EVAR) has
emerged as the treatment of choice for many patients with
an abdominal aortic aneurysm (AAA). Recent prospective
studies have documented that short-term morbidity and
mortality are improved with EVAR compared with open
repair.1,2 One potential limitation to the use of EVAR in
the medically compromised patient, for whom EVAR is of
particular advantage, is the existence of renal dysfunction
(serum creatinine, 1.5 mg/dL). The need for significant
volumes of nephrotoxic iodinated contrast for preoperative
assessment and endograft placement may aggravate pre-
existing renal dysfunction and accelerate the appearance of
end-stage renal disease in selected patients. In addition,
there is evidence to suggest that the nephrotoxic effects of
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sient but rather permanent and cumulative.3
An alternative contrast approach for EVAR is the use of
carbon dioxide (CO2) and CO2 digital subtraction angiog-
raphy (CO2-DSA), which was first described for diagnostic
purposes by Hawkins.4 Although the use and value of
CO2-DSA in the diagnostic setting is well established,
5 its
safety and efficacy in guiding endovascular interventions
and EVAR in particular has not been carefully studied or
conclusively established.
We have extensive experience with CO2-DSA.
6-9 Since
2003, our group has used it as the preferential imaging
technique for EVAR candidates who have pre-existing re-
nal dysfunction. This report analyzes the safety and efficacy
of CO2-DSA for EVAR in a group of patients with renal
insufficiency compared with a concurrent group of patients
with normal renal function undergoing EVAR with iodin-
ated contrast (ICA).
PATIENTS AND METHODS
This is a retrospective cohort study of 100 consecutive
patients treated by EVAR at the University of Southern
California University Hospital between 2003 and 2005.
The chart of each patient was retrospectively reviewed and
data recorded in an investigational database. The research
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Among the preoperative variables recorded were de-
mographics and risk factors (diabetes mellitus, hyperten-
sion, coronary artery disease, and tobacco use), body mass
index, and serum creatinine concentration. Estimated glo-
merular filtration rate (eGFR) was calculated using the
Cockroft and Gault formula: GFR [(140 – age)weight
in kg]/[72 serum Cr in mg/dL] f(P), where f(P) 1
for males and 0.85 for females. EVAR intraoperative vari-
ables of graft type, fluoroscopy time, total radiation expo-
sure (dose-area product), operative time, iodinated con-
trast volume, use of CO2, use of gadolinium and volume,
presence of endoleak, and type and number of graft extend-
ers were recorded.
Postoperative variables included serum creatinine con-
centration and eGFR on postoperative day 1 and at dis-
charge, intensive care unit stay, hospital length of stay,
postoperative morbidity, and mortality. Results of postop-
erative endograft imaging by computed tomography (CT),
ultrasonography, or both, and the need for endograft revi-
sion at 1 and 6 months were recorded.
For purposes of analysis, preoperative renal function
was used to categorize patients into one of two groups.
Group I patients had normal renal function as evidenced by
a serum creatinine 1.5 mg/dL and the EVAR was per-
formed exclusively with iodinated contrast (ISOVUE 300,
Bracco Diagnostics, Princeton, NJ). Group II patients had
chronic renal insufficiency as defined by a serum creatinine
1.5 mg/dL and the primary intravascular contrast agent
was CO2. When suboptimal imaging with CO2-DSA oc-
curred, CO2-DSA was supplemented with gadolinium or
iodinated contrast.
The primary end points of successful graft placement,
renal function, and the need for graft revision were com-
pared between the two groups. Other secondary end points
for comparison included endoleak type and frequency and
perioperative morbidity and mortality.
The technique of CO2-DSA involves the following
(Fig 1)6,7: A sterile bag (Angioflush 3 fluid collection bag,
Angiodynamics, Queensbury, NY) with attached tubing
(Connecting tube, Boston Scientific, Natick, Mass) with a
stopcock is inflated with CO2. The bag is purged and
inflated with CO2 three times to eliminate the possibility of
room air contamination. The attached stopcock is closed,
the inflated bag disconnected, and then connected to tub-
ing (Angioflush fluid management system tubing, Angio-
dynamics) with one-way valves and a sidearm. The end of
the catheter contains a three-way stopcock and is con-
nected to the intra-arterial injection catheter. The sidearm
of the tubing is connected to a 60 mL Luer lock syringe.
With the three-way stopcock open to air and closed to the
injection catheter, the syringe is filled and purged at least
three times to rid the syringe and tubing of room air. After
the final filling, the stopcock is closed to air and open to the
injection catheter, creating a closed CO2 system.
Hand injection of 50 mL using digital subtraction
imaging is used for angiography. Because CO2 is rapidlysoluble in blood and disappears quickly, high frame rates of
3 to 6 frames per second are necessary. Stacking technology
is used to combine frames and produce a single image for
viewing, if necessary. Multiple injections in various imaging
planes, rotation of the patient, or both, are sometimes
necessary to demonstrate the relevant anatomy and to
remove the vessel from overlying bowel gas or bone.
Indications for EVAR included patients with infrarenal
AAA 5.0 cm with favorable endovascular anatomy. Im-
aging evaluation included spiral CT angiography (CTA)
with axial and coronal reconstructions to evaluate anatomy.
For group II patients, preoperative planning and postoper-
ative endograft surveillance were done with a combination
of imaging techniques that included noncontrast CT, aortic
duplex imaging, and magnetic resonance imaging (MRI).
In all patients, hydration was initiated preoperatively,
and group II patients received either pretreatment with
N-acetylcysteine, intravenous bicarbonate, or a combina-
tion of the two. EVAR was performed with Ancure
(Guidant, Indianapolis, Ind), Excluder (W.L. Gore & As-
soc, Flagstaff, Ariz), AneuRx (Medtronic, Sunrise, Fla), or
Zenith (Cook, Bloomington, Ind) endografts. All cases
were performed under general anesthesia in a dedicated
operating suite with fixed angiographic equipment (Phillips
Allua 2001, Bothell, Wa).
The EVAR procedure consisted of bilateral groin access
and initial angiography for localization of the renal and
hypogastric arteries and definitive sizing of graft length.
The main body of the graft was deployed in the infrarenal
position after one or two angiograms with magnified views
were performed of the perirenal aorta. After deployment,
placement of the contralateral limb, and the ipsilateral limb
in cases of the Zenith graft, was completed by using angio-
grams for localization of the hypogastric arteries. A final
angiogram was used to evaluate for endoleaks and final
graft position. Additional angiographic runs were used if an
endoleak was detected that required additional interven-
tion or placement of additional graft extensions. All type I
and III endoleaks were addressed. Detected type II en-
doleaks were observed.
Statistical comparison of preoperative, intraoperative,
and postoperative variables for groups I and II was per-
formed using 2 analysis for random ordinal variables, the
Fisher exact test for nonrandom variables, and the Student
two-tailed t test for comparison of continuous variables. A
value of P  .05 was considered significant.
RESULTS
Between 2003 and 2005, 100 patients (84 in group I
and 16 in group II) underwent EVAR. The average patient
age was 76 years, and 67% were men. The groups had
similar preoperative demographics and risk factors, al-
though a trend was noted towards an increased incidence of
coronary artery disease in group II (30% group I vs 60%
group II, P  .06; Table I). Patients in group II had a mean
preoperative serum creatinine of 1.8 mg/dL and eGFR of
36 mL/(min · 1.73 m2) and group I patients had a mean
creatinine of 1.0 mg/dL and eGFR of 81 mL/(min · 1.73
bon
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groups by the National Kidney Foundation classification
for chronic kidney disease. No patient in either group was
on dialysis.
Endografts placed included 8 Ancure, 2 AneuRx, 81
Excluder, and 9 Zenith. The amount of iodinated contrast
necessary for endograft placement differed significantly at
148 mL in group I vs 27 mL in group II (P  .005).
Thirteen (80%) patients in group II received either supple-
mental gadolinium (40 mL in a single patient) or iodinated
contrast (mean volume, 23 mL in 12 patients). Operative
time was shorter in group I (140 minutes vs 180 minutes,
P  .05) as was fluoroscopy time (24 minutes vs 46
minutes, P  .01). Total radiation exposure was lower in
group I at 529 Gy/cm2 vs group II at 925 Gy/cm2 (P 
.04). There was no difference in the other intraoperative
Fig 1. Line drawing shows carvariables examined (Table III).A total of 66 intraoperative endoleaks were detected in
56 patients: Ia in 28, Ib in 6, II in 31, and III in 1. All but
two type I endoleaks were successfully managed intraoper-
atively by either redo balloon angioplasty at the attachment
site or placement of additional components. There was no
significant difference between groups in the total or types of
endoleaks detected (Table IV). When used in group II, the
use of supplemental iodinated or gadolinium contrast an-
giograms did not demonstrate endoleaks not previously
seen with CO2-DSA.
Overall mean postoperative serum creatinine and eGFR
were unchanged from preoperative levels in both groups
both on postoperative day 1 and at discharge. One patient
in group 2 had a significant increase (20%) in serum
creatinine. This patient received 40 mLs of gadolinium, but
no iodinated contrast. The serum creatinine level increased
dioxide (CO2) delivery system.from a preoperative value of 2.2 to 3.0 mg/dL on the first
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line by discharge. Serum creatinine values recorded in this
patient 3 months before EVAR were from 2.2 to 3.5
mg/dL. No patient in either group required dialysis post-
operatively or during follow-up.
Group I and group II were not significantly different in
mean hospital length of stay (2.0 vs 3.9 days), mean length
of intensive care unit stay (0.64 vs 0.86 days), and postop-
erative morbidity (6% vs 12%). Specific postoperative com-
Table I. Preoperative variables
Characteristic*
Group I Group II
Pn  84 (%) n  16 (%)
Male (n) 69 (82) 15 (94) NS
Age (years) 76 (54-93) 77 (59-89) NS
CAD 25 (30) 10 (60) NS
Hypertension 50 (60) 11 (70) NS
Tobacco use 67 (80) 13 (80) NS
COPD 8 (10) 3 (20) NS
Diabetes mellitus 10 (12%) 3 (20%) NS
Aneurysm size (cm) 5.8 (4.5-7.5) 6.4 (4.7-11) NS
Serum creatinine 1.0 (0.5-1.6)† 1.8 (1.5-3.2) .05
Estimated GFR 81 (22-167) 36 (15-63) .05
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease; GFR, glomerular filtration rate.
*Categoric data are presented with percentages; continuous variables are
presented as means (range).
†One patient had an admission creatinine of 1.6 mg/dL, all prior 1.5 so
the procedure was done with iodinated contrast only and included in group I.
Table II. Chronic kidney disease stage for patients in
groups I and II
GFR CKD stage*
Group I
n  84 (%)
Group II
n  16 (%)
90 1 29 (35) 1 (6)
60-89 2 27 (32) 1 (6)
30-59 3 25 (30) 10 (63)
15-29 4 3 (4) 4 (25)
15 5 0 0
GFR, glomerular filtration rate; CKD, chronic kidney disease.
*Stages CKD as defined by the National Kidney Foundation (www.kidney.
org).
Table III. Intraoperative variables
Characteristic*
Group I Group II
P(n  84) (n  16)
Iodinated contrast
dose (mL) 148  20 27  5 .005
Fluoroscopy time (min) 24  1.5 46  7 .01
Total radiation (Gy/cm2) 529  44 925  138 .04
Endoleak detected 43 (51%) 10 (63%) NS
Operative time (hours) 2.3  0.2 3.0  0.3 .05
Graft extenders 0.4  0.05 0.5  0.13 NS
Hypogastric embolization 0.18  0.04 0.38  0.11 NS
*Continuous variables are expressed as mean  standard error of the mean.plications in group I were one patient each with unplannedhypogastric artery coverage, myocardial infarction, urinary
retention, femoral arterial-venous fistula, and retroperito-
neal bleed requiring transfusion; and in group 2, one
patient each with iliac artery dissection, paraplegia, and
femoral pseudoaneurysm. No deaths occurred in either
group (Table V).
At 1 month postoperatively, the incidence of endoleaks
detected by imaging was 13% in group I vs 18% in group II
(P  NS). Five type II endoleaks (four in group I and one
in group II) not seen intraoperatively were detected at 1
month. Endoleak incidence was unchanged on 6-month
endograft imaging studies (group I, 10% vs group II, 18%;
P  NS). Diagnostic angiograms for possible type I en-
doleaks that were determined to be type II endoleaks were
performed in two group I patients. No remedial procedures
were required in either cohort at 6 months.
DISCUSSION
Pre-existing chronic kidney disease occurs in approxi-
mately 7% to 25% of patients undergoing EVAR.10,11 The
reported incidence of acute renal failure after EVAR varies
owing to differences in reporting standards but is between
2% and 16%, and recent studies confirm an associated
mortality of 30% to 50% 3,12,13 Although pre-existing renal
insufficiency carries the highest risk of post-EVAR renal
failure, patients with normal preoperative serum creatinine
values are not immune, and in a standard-risk group
showed a 2.5% incidence of renal dysfunction when defined
as a serum creatinine increase of 30%. Notably, when fol-
lowed out to 1 year, the incidence of renal dysfunction
Table IV. Intraoperative endoleaks by specific type
Type Group I* Group II† OR (95% CI) P
Type Ia 24 (29%) 4 (25%) 1.2 (0.4-4.1) NS
Type Ib 4 (5%) 2 (13%) 0.4 (0.1-2.1) NS
Type II 26 (31%) 6 (24%) 0.7 (0.2-2.3) NS
Type III 1 (1.2%) 0 (0%) N/A NS
OR, Odds ratio; CI, confidence interval; N/A, not applicable.
*Group 1: 53 endoleaks detected in 43 patients.
†Group 2: 12 endoleaks detected in 10 patients.
Table V. Postoperative variables
Characteristic Group I Group II P
LOS 2  0.2 3.9  1 NS
ICU LOS 0.9  0.1 .64  0.3 NS
Post-op creatinine
(mg/dL) 0.9  0.03 1.8  0.14 .0002
Creatinine change
(mg/dL)* –0.06  0.02 0.01  0.07 NS
Morbidity 6% 12% NS
Mortality 0 0 NS
LOS, Length of stay; ICU, intensive care unit stay length.
*Creatinine change is difference between admission and discharge serum
creatinine level.increased to 16% in this same cohort.3
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risk patients, particularly those in the geriatric age group
who have diminished muscle mass because of aging, is that
the serum creatinine level can be a very inaccurate indicator
of overall renal function. Our observation that a mean
serum creatinine of 2 mg/dL was associated with a
critically reduced mean eGFR of 36 mL/(min · 1.73 m2)
supports this explanation and argues that any reported
clinical assessment of renal function should, at the very
least, be indexed by body mass.
From open surgical data, it has been reported that
patients with pre-existing renal dysfunction have a dispro-
portionately high risk of perioperative morbidity (30% vs
13%) and acute renal failure.14 Whether EVAR might
lessen the morbidity and incidence of renal decompensa-
tion in this particular patient population is unknown.
Greenberg et al3 analyzed 279 patients undergoing open
and EVAR with suprarenal fixation and saw an early renal
benefit in renal function in the endovascular group. When
the open group who required suprarenal cross-clamping
was eliminated, however, the incidence of acute renal fail-
ure was equivalent.
Acute renal decompensation after endovascular or
open repair has a number of causes.15,16 Common reasons
attributed to open surgery are renal or suprarenal cross-
clamping, blood loss, hypotension, ischemia–reperfusion
injury, and manipulation of thrombus, with renal paren-
chyma microembolization leading to activation of vasoac-
tive components, endothelial damage, and cytokine release.
Although many of these same factors can occur with EVAR,
endovascular aortic procedures add the additional renal
insult of iodinated contrast. With both intraoperative place-
ment and postoperative surveillance by CT of aortic en-
dografts contrast, the cumulative dose of nephrotoxic con-
trast becomes significant over time. Greenberg et al3 have
stated that this repetitive use of iodinated contrast and the
nephrotoxic insult incurred may be responsible for the
observed deterioration in renal function after endograft
replacement.
Previous studies have documented the risks of renal
failure after diagnostic ICA. Moore reported an 11% rate of
acute renal failure in 400 patients who underwent aortog-
raphy. In the group with pre-existing renal dysfunction,
acute renal decompensation developed in 42%, and 8%
required dialysis.17 In a series of 164 patients undergoing
EVAR, Walker et al13 documented a mortality of 47% in the
15 patients with preoperative renal impairment and 2.7% in
those with normal renal function. More recent reports
suggest that acute renal decompensation after diagnostic
angiography is currently less common owing to a more
judicious use of iodinated contrast as well as a combination
of strategies aimed at reducing the risk of post contrast
nephropathy.
These proposed strategies include the use N-acetylcysteine
(Mucomyst, Roberts Pharmaceuticals, Eatontown, NJ),
dilution of iodinated contrast, intravenous bicarbonate in-
fusions, mannitol, fenoldopam, robust preprocedure and
postprocedure hydration, and in selected circumstance, theuse of gadolinium. We have found all these modalities
empirically useful in selected patients but each with intrinsic
limitations. For example, the contrast agent gadolinium
appears to be a simple and reasonable alternative to iodin-
ated contrast. In practice, however, the recommended dos-
age of 0.3 to 0.4 mmol/kg calculates to only 30 mL, and
when doubled to its maximum, allows for only 60 mL.
Although adequate for MRI, this dose is inadequate as a
stand-alone agent for EVAR. In addition, those who have
tried dilute gadolinium have been disappointed with its
attenuating ability.18 Other limitations include hyperos-
molarity and cost, and recent reports suggest that gadolin-
ium may be nephrotoxic as well.19-21 This may have been
the cause of the transient rise in serum creatinine in one
patient who underwent CO2-DSA supplemented only with
gadolinium.
Several groups have reported CO2-DSA to be safe and
useful.5-9 Its mechanism is the transient displacement of
arterial blood, providing a contrast image. Because of its
buoyancy, visualization of dependent vasculature may be
limited. Operators have circumvented this shortcoming by
changing the patient position to place the area of interest in
a nondependent position. In an experience with 800
cases of CO2-DSA, we have found these maneuvers to be
rarely necessary. In most cases, simple repositioning of the
injection catheter and reinjection of CO2 in different pro-
jection planes yields adequate views. Others have described
the importance of using a specialized injector to achieve
optimal angiography and avoid inadvertent introduction of
air. We use a simple hand-injection method and closed
system that includes a 60 mL syringe, three-way stopcock,
and a bag of CO2.
Although some question the safety of CO2-DSA, we
have found it to be a safe and valuable technique. In a
recent review of 605 CO2-DSA procedures performed at
our institution for a variety of endovascular interven-
tions, adverse events occurred in 5.1% (31/605) and
included abdominal pain in 8, puncture site hematoma in
11, transient hypotension in 4, nausea in 3, and 1 patient
each with renal failure, chest pain, localized aortic dis-
section, hives, and paresthesia. Two patients had persis-
tent abdominal pain after aortography associated with
hyperamylasemia and clinical evidence of pancreatitis.
One died, for a mortality rate of 0.17%; however, the role
of CO2-DSA in that death is uncertain because micro-
vascular cholesterol emboli were found at autopsy
(Hood DB, Hua HT, Weaver FA. Carbon dioxide digital
subtraction angiography: is it safe? Personal communi-
cation.)
The application of CO2-DSA for EVAR has previously
been suggested by Gahlen et al,22 who reported its use in
three patients. Our report adds 16 patients and compares
them with a concurrent group undergoing EVAR. The use
of CO2-DSA permitted a significant reduction in iodinated
contrast use and minimized post-EVAR deterioration in
renal function in patients with pre-existing azotemia. In
three patients, EVAR was performed exclusively with CO2.
Successful endograft placement was possible in all 16 pa-
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endoleaks in groups I and II was similar. Of interest is our
observation that CO2, because of its lower viscosity, is
actually more sensitive in documenting intraoperative en-
doleaks than iodinated contrast. A prospective trial at our
institution to further investigate this clinical observation is
in progress.
Subsequent 6-month clinical follow-up and graft sur-
veillance documents equivalency for endoleak incidence
and the need for endograft revision. One caveat to this
Fig 2. A, Iodinated contrast angiogram of completed EVAR.
B, Comparison study using carbon dioxide digital subtraction
angiography.observation is that postoperative imaging for group II didnot include the use of iodinated contrast CT, but relied on
duplex, noncontrast CT, and MRI. As a consequence,
some endoleaks, particularly small low-flow type II en-
doleaks, could have been missed in group II.
An observation not previously noted concerning CO2-
DSA for EVAR is the significant increase in radiation expo-
sure documented in group II patients. There are a number
of possible explanations for this finding.
First, adequate CO2-DSA imaging does require an
increase in frame rate from the customary two frames per
second for iodinated contrast to six frames per second.
This more than doubles the radiation exposure for each
CO2-DSA run compared with iodinated contrast. In
addition, we also documented that total fluoroscopy
time was approximately doubled in group II cases. This
Fig 3. Type II endoleak intraoperatively documented by (A)
iodinated contrast and (B) carbon dioxide digital subtraction
angiography. Arrows point to feeding lumbar arteries.could have been due to increased technical complexity in
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numeric but not statistically significant increases in the
average number of graft extenders and the requirement
for hypogastric artery embolization in group II cases
lends support to this possibility. That total operative
time was also significantly increased in group II lends
additional support.
An alternative explanation however, includes either
difficulty with CO2 delivery or, more likely, poor image
resolution with CO2-DSA necessitating the use of iodin-
ated contrast and a “repeat run” of the same area of interest.
This was certainly the case in 13 patients in group II in
which some iodinated contrast or gadolinium was neces-
sary.
The significance of this finding must be considered in
the context of lifetime diagnostic and therapeutic radia-
tion exposure. The difference of approximately 400 Gy/
cm2 in average dose-area product between group I and II
is roughly equivalent to 6,000 mrem. A standard abdom-
inal CT angiogram exposes the patient to 144 Gy/cm2
(2000 mrem).23,24 Consequently, the incremental in-
crease in radiation exposure in group II is roughly equiv-
alent to three additional CT scans over the life of the
patient.
The effects of increased exposure to the operating team
should also be commented on. The average radiology
technician in our institution receives about 20 to 30 mrem
a month (with detectors worn on the outside of lead
shielding), with a maximum allowable exposure of 5000
mrem a year. As a point of reference, the average American
is exposed to 360 mrem a year, mostly from terrestrial
causes. It is estimated that the chance of cancer increases
10% after a total exposure of 250,000 mrem. The contri-
bution of CO2-DSA in this context appears to be negligi-
ble, particularly if appropriate shielding and wearing of lead
aprons is followed.
CONCLUSION
This experience documents CO2-DSA–directed
EVAR to be a safe and effective strategy for reduction of
contrast nephrotoxicity in the azotemic patient. The
reduction in iodinated contrast use is accompanied by
post-EVAR stability in renal function that is superior to
the 2% to 16% incidence of renal deterioration that is
reported in the literature. This salutary short-term out-
come is accompanied by a late endoleak incidence and
endograft revision rate that is equivalent to patients
undergoing EVAR with iodinated contrast. These posi-
tive outcomes are tempered by the finding that CO2-
DSA for EVAR does prolong fluoroscopy times and
increases radiation exposure to both patient and operat-
ing room personnel (Figs 2 and 3).
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Dr Roy Fujitani (Orange, Calif). Good morning, members
and guests. Alex, that was a very well presented paper. The USC
vascular surgery group has very nicely reported their continued
experience with the use of carbon dioxide as an alternative to
iodinated contrast material. Their experience dates back to 1991
when it was first reported by Fred Weaver and the authors at USC
who had published their clinical applications of CO2 angiography
in the Journal of Vascular Surgery. In this series, the authors report
contemporary utility of CO2 digital subtraction angiography in
imaging 16 of 100 patients who underwent endovascular aortic
aneurysm repair with associated renal insufficiency over a 2-year
period of time. The use of CO2 DSA helped protect renal function
by lessening the need for iodinated contrast material with effective
imaging quality but resulted in longer fluoroscopic and operating
times.
Now Dr Chao, as part of my discussion, I will intersperse four
questions for you to consider. Since carbon dioxide is approxi-
mately 20 times more soluble than oxygen, the carbon dioxide
bubbles completely dissolve within 2 to 3 minutes after being
injected into the vessel and it is eliminated through the respiratory
system, but I would be concerned that in using carbon dioxide in
patients with very advanced pulmonary compromise or insuffi-
ciency, such as someone with COPD who is a carbon dioxide
retainer or those patients who have pulmonary hypertension, the
diagnostic doses of CO2 may increase pulmonary arterial pressure.
Additionally, patients with right-to-left shunts may be at risk for
paradoxical gas embolism. This leads to my first question. Are there
any absolute contraindications in the use of carbon dioxide as a
contrast agent?
As you alluded, the incorrect technique may result in con-
tamination of CO2 gas with atmospheric air and this will result
in very serious complications since atmospheric air is much less
soluble in the blood than carbon dioxide. Additionally, even
without contamination, if enough carbon dioxide gas is trapped
within a large abdominal aortic aneurysm and it persists, it may
allow gas exchange between the carbon dioxide and nitrogen
within the blood. This exchange may result in visceral ischemia
due to vacuum locking within the mesenteric arteries. In your
manuscript, you alluded to one patient having developed pan-
creatitis, and I wonder if this may not have been the mechanism
that had occurred due to ischemia of the visceral circulation.
There is need to be very careful in timing of consecutive
injections of carbon dioxide—and I think you mentioned 2 min-
utes—to prevent the localized accumulation of gas bubbles, which
may produce a clinically significant gas embolism. My next ques-
tion, therefore is, is there a maximum volume in a single injection
that prevents gas accumulation that may result in nitrogen disso-
lution and/or vapor locking?
Since carbon dioxide is lighter than blood plasma and floats on
the surface of the blood, once injected into large vessels such as the
aorta or inferior vena cava, carbon dioxide bubbles flow along thealong the posterior portion. Because of the anterior origin the
celiac vessels, the superior mesenteric arteries may be very well
visualized even with smaller volumes. It has been reported that
perhaps vessels that are smaller than 10 mm are best imaged with
CO2 angiography because then it disperses within 80% of the
volume of blood. My next question therefore would be, is there a
critical maximal diameter of the vessel or aneurysm where the
buoyancy of carbon dioxide gas can be problematic, not allowing
complete visualization of the lumen and, therefore, having a dete-
rioration in the quality of the imaging?
All in all, carbon dioxide seems to have very notable advan-
tages compared to iodinated contrast material. It has no allergic
reactions. There is no renal toxicity. There does not appear to be
any hepatic toxicity, and you can go on to inject unlimited amounts
of carbon dioxide in vascular imaging because the gas is effectively
eliminated by means of respiration. Finally, compared to nonionic
contrast agents and gadolinium-based types of agents, it is rela-
tively cheap. I checked with our purchasing department and con-
trast agents tend to be a little over $1 per cc, whereas CO2 is less
than a penny.
My final question: with so many advantages of CO2 DSA, has
your group at USC considered performing all of its angiographic
studies using this agent instead of iodinated contrast?
I want to thank the program committee for the privilege and
opportunity to presents questions on this paper. Thank you.
Dr Alexander Chao. Thank you, Dr Fujitani, for your
comments. In regards to your first question regarding any
absolute contraindications to the use of CO2 : although there
are contraindications to its use in certain procedures such as
cerebral angiography, we have not found CO2 to be contrain-
dicated in any single patient population. As you mentioned,
there are descriptions of concern with use of CO2 in patients
with severe COPD. Although we did not look at the severity of
the COPD or any associated pulmonary hypertension, we have
not found it to be a problem either in this study or in our
previous experience.
Your second question concerned the maximum volume of
CO2 in a single injection that prevents accumulation. We cur-
rently use a 50-cc syringe bolus injection by hand with 2-minute
intervals between injections. I am not aware of any human
studies, but there were many dog studies that looked at volume.
Rapid intravenous and intra-arterial injections of 7.5 milliliters
per kilogram repetitively and continuous infusions of 100 mil-
liliters per kilogram intravenous for up to 10 L of CO2 were safe.
Even injections of 7 milliliters per kilogram directly injected
into canine renal arteries caused no complications in the supine
position.
You talked about the vapor lock. Yes, there have been
sporadic reports in the literature of complications that are
thought due to vapor lock, with the greatest number of cases
seen in the smaller series. I think these reports may play a large
part in preventing wider use of CO2 . I do not really have an
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that it may be due to accidental contamination of room air into
the injection. There are many different injection techniques
currently in use. Notably, one group has described relying on
automated injectors to prevent contamination by room air. We
continue to have confidence in hand injection with attention to
frequent purging. It is also important to ensure proper tighten-
ing of the seals on the lure-locks to, again, avoid unintentional
withdrawal of air into the system.
Is there a critical maximum diameter of an aneurysm? I
think that is going to be a hard one to answer. Your description
of the physiology of CO2 gas in the vascular system was most
thorough. Unfortunately, my answer is much less impressive.
We routinely image large aortic aneurysms well over 5 cm in
diameter, while on the other end of the spectrum, we have
reported in our experience with studying renal arteries as well as
distal tibials with CO2 .
I think a large determinant of image quality depends on the
injection catheter positioning and imaging angle. Initially, we
frequently tried patient repositioning in regards to the buoy-
ancy you mentioned, but we really have abandoned that re-
cently, and find that with proper catheter positioning, you can
get excellent contrast imaging in large as well as smaller vessels.
Your final question, with the many advantages of the CO2 we
purport, should we consider using it in all patients? I think that is a
very good question. We have currently at USC initiated a prospec-
tive nonrandomized study looking at CO2 versus iodinated con-
trast in each patient in attempt to get a better idea of the exact
sensitivity of CO2 gas in detecting endoleak during EVAR. We are
considering increasing our use of CO2 in the elderly patient
population where the creatinine level may not be as sensitive an
indicator of true renal function. We are trying to more consistently
use the calculated estimated GFR.
Dr Willis Wagner (Los Angeles, Calif). A very nice presenta-
tion. Based on the leadership role that Fred Weaver and Doug
Hood have shown us in the use of CO2 , we actually have a large
experience with using CO2 in patients with renal insufficiency.
However, 2 years ago, I did have a case that has tempered our
enthusiasm, and I would like to get some feedback from you. We
had a patient who was having a CO2 angiogram for occlusive
disease who developed massive fatal emboli to everything below
the diaphragm, unlike anything I had ever seen with patients
having standard contrast angiograms. Due to lack of autopsy, we
were unable to identify the cause of the embolization, but I am just
wondering whether you have seen this and whether this was in fact
related to the CO2 or just the fact that the patient had the
angiogram.
Dr Chao. What you describe is actually very similar to a case
report in the literature attributed to CO2 aortic angiography. This
is something we thought about, but obviously, I cannot answer
that definitively. We did not have any problems during this study,
but our previous series of 600 CO2 angiograms in patients from
1985 to 1995 did have one fatality that was due to what was
initially thought to be small bowel vapor lock. That patient actually
had an autopsy and was found to have multiple severe cholesterol
microemboli in the small bowel. Similar to the risks of high-
pressure injection during regular iodinated contrast angiography,
the power injection of the CO2 may also cause fragmentation of
unstable aortic debris.
This brings up a technical point I failed to mention. Due to the
compressible nature of the CO2 gas, during a rapid 60-cc manual
injection the majority of the CO2 is not actually expelled until the
syringe is nearly empty. It is a good idea to ease off a little at the end
of the injection to avoid too high a pressure at the delivery end.
Others have suggested that all injections be done with an auto-
mated injector to prevent overpressurization, but once again, we
do not really find that to be a problem currently.
Dr J. Dennis Baker (Los Angeles, Calif). Why did you have
such a substantial increase in your fluoroscopy time and radiation?Can you explain why it takes so much more radiation to complete
the task with carbon dioxide?
Dr Chao. That was something that was a little bit of a
surprise when we sat down and looked at the data, but the total
radiation as measured by DAP is easy to explain. Normally for
angiography we use either two or three frames per second,
usually two frames per second. For the CO2 , we really have
found it necessary to go to six frames per second. As you know,
the runs really count for most of the patient radiation exposure.
The fluoroscopy time was also increased significantly, here
almost doubled by number, and I do not really have a good
explanation of that. When we looked, we did have—I think it
was—38% in group 2 requiring hypogastric artery embolization
and a smaller percentage in group 1. Group 2 patients I think
overall tended to be somewhat more complicated. We saw a
trend in a greater number of graft components used and the
longer operative times. The CO2 itself does not increase the
operative time at all, so I think it may have just been part of the
patient population that explains the increase in fluoroscopy
time.
Dr Benjamin Starnes (Seattle, Wash). Alex, that was a very
nice presentation. I have a couple of questions. In my experi-
ence with CO2 angiography, especially with the patient awake,
one injects the CO2 and the patient complains of severe abdom-
inal pain and then moves all over the place and that certainly
affects the imaging quality substantially. If you are doing these
under local or regional anesthesia, perhaps that is an explanation
as to why you have increased your fluoroscopy time. Are you
having to put every single patient under general anesthesia to
use this technique? One would think that this would add to the
morbidity profile.
The second question is, why not use IVUS to precisely locate
your pelvic vessels and be able to precisely place your graft? I use
IVUS quite often for this purpose and I think that it is an attractive
alternative over CO2 .
Dr Chao. We have had some experience with IVUS use in the
past and again recently for thoracic endograft placement but have
not enough experience to become proficient or have a personal
opinion on its utility. Additionally, for routine EVAR, the acqui-
sition cost versus patient benefit is somewhat prohibitive. All the
patients in this series received general anesthesia. In regards to
lower extremity CO2 angiography, we have found the DS to be no
more or less than with iodinated contrast.
Dr Timothy Chuter (San Francisco, Calif). I notice you
use on average 27 milliliters of contrast. We have been able to
use even lower volumes of contrast without using CO2 . We
perform selective angiograms of the renal arteries using bright-
tip catheters and little puffs of half-strength contrast. In fact, we
have inserted multibranched stent grafts for TAAA using as little
as 25 milliliters of contrast. Have you tried selective angiogra-
phy as an alternative to CO2 angiography, which seems to
involve intubating the patients and spending a lot of extra time
in the OR?
Dr. Chao. That is very impressive and I have heard descrip-
tions from your institution regarding very low volumes of contrast.
Dr George Andros (Los Angeles, Calif). Under Fred’s goad-
ing and Nick Nelken’s persistence, we instituted a CO2 angiogra-
phy program many years ago. Because we have a lot of diabetics in
our practice, we use it very commonly for bilateral renal stenting
and all sorts of infrainguinal work, but not for aneurysms so far.
And it’s cheap!
Isn’t it a little disingenuous to say you only use 27 cc of
contrast when nearly all patients are evaluated with followup CT
angiography? Is this your imaging policy, or are you doing fol-
lowup studies with duplex? We heard earlier today that, on average,
patients treated with EVAR will have a measurable decline in renal
function when checked 1 year postoperatively. If you are econom-
ical with iodinated contrast as you suggest, have you also observed
this deterioration in kidney function or are the patients spared this
complication by using CO2 and duplex?
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opportunity to discuss the importance of cumulative contrast
toxicity. Greenberg’s recent data suggest a cumulative effect on the
kidneys. Going by our protocol, in any patient with baseline renal
insufficiency, we avoid contrast during preoperative or postopera-
tive CTs unless absolutely necessary. We have previously demon-
strated excellent correlation in our institution between duplex
imaging and CT, so we either obtain duplex preoperatively or MR
angiography. Preoperatively we follow by duplex only on these
patients so there is no other cumulative contrast insult.As far as the BUN and creatinine, it is a problem. In this day
and age, it is difficult to get follow-up labs on patients. We only had
post-op inpatient and discharge labs; however, we do know that no
patient required dialysis at any point for contrast-induced renal
failure.
Dr Chuter. I have to respond to the word disingenuous. I
do not think anybody would advocate using CO2 outside of the
setting of the stent graft implantation, so that is where I was
focusing my comments and that is what the 25 milliliters
refers to.
